Related Experiment Video
Updated: Aug 21, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Venous thromboembolism among Medicare acute ischaemic stroke patients with and without COVID-19
Xin Tong1, Quanhe Yang2, Ganesh Asaithambi3
1Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA xtong@cdc.gov.
Insights
Patients with acute ischemic stroke (AIS) and a history of COVID-19 have a higher risk of venous thromboembolism (VTE). This increased VTE prevalence highlights the need for vigilant monitoring and prompt intervention in these vulnerable individuals.
Area of Science:
- Cardiovascular Medicine
- Infectious Diseases
- Hematology
Background:
- COVID-19 infection is linked to an elevated risk of venous thromboembolism (VTE).
- Acute ischemic stroke (AIS) patients face a heightened risk of VTE.
- The interplay between COVID-19 history and VTE risk in AIS patients requires further investigation.
Purpose of the Study:
- To determine the prevalence of VTE in acute ischemic stroke (AIS) patients with and without a history of COVID-19.
- To compare VTE rates between AIS patients with prior COVID-19 exposure and those without.
- To quantify the association between COVID-19 history and VTE risk in AIS patients.
Main Methods:
- Retrospective cohort study of Medicare fee-for-service (FFS) beneficiaries aged ≥65 years.
- Inclusion of patients hospitalized for AIS between April 1, 2020, and March 31, 2022.
- Comparison of VTE prevalence and adjusted prevalence ratios based on COVID-19 history.
Main Results:
- VTE prevalence was 4.51% in AIS patients with hospitalised COVID-19, 2.96% with non-hospitalised COVID-19, and 2.61% in those without COVID-19.
- AIS patients with a history of hospitalised COVID-19 had 1.62 times greater VTE prevalence compared to those without COVID-19.
- AIS patients with a history of non-hospitalised COVID-19 had 1.13 times greater VTE prevalence compared to those without COVID-19.
Conclusions:
- A significantly higher prevalence of VTE exists among Medicare beneficiaries with AIS and a history of COVID-19.
- Early identification of coagulation abnormalities in these patients is crucial.
- Prompt and appropriate interventions may improve clinical outcomes for AIS patients with COVID-19 history.
Background:
COVID-19 is associated with an increased risk of venous thromboembolism (VTE). This study examined the prevalence of VTE among acute ischaemic stroke (AIS) patients with and without a history of COVID-19.
Methods:
We identified AIS hospitalisations of Medicare fee-for-service (FFS) beneficiaries aged ≥65 years from 1 April 2020 to 31 March 2022. We compared the prevalence and adjusted prevalence ratio of VTE among AIS patients with and without a history of COVID-19.
Results:
Among 283 034 Medicare FFS beneficiaries with AIS hospitalisations, the prevalence of VTE was 4.51%, 2.96% and 2.61% among those with a history of hospitalised COVID-19, non-hospitalised COVID-19 and without COVID-19, respectively. As compared with patients without a history of COVID-19, the prevalence of VTE among patients with a history of hospitalised or non-hospitalised COVID-19 were 1.62 (95% CI 1.54 to 1.70) and 1.13 (95% CI 1.03 to 1.23) times greater, respectively.
Conclusions:
There appeared to be a notably higher prevalence of VTE among Medicare beneficiaries with AIS accompanied by a current or prior COVID-19. Early recognition of coagulation abnormalities and appropriate interventions may help improve patients' clinical outcomes.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Pulmonary Embolism III: Nursing Management

